ESR1 and breast carcinoma: Targeted therapies for ER+ breast cancer include endocrine therapies such as tamoxifen and aromatase inhibitors, which block estrogen signaling, and CDK4/6 inhibitors such as palbociclib and ribociclib, which inhibit cell cycle progression when combined with endocrine therapy [4].